



## Hepcludex<sup>®</sup> (bulevirtide-gmod)

# Treatment Duration and Discontinuation of Therapy

This document is in response to your request for information regarding the use of Hepcludex<sup>®</sup> (bulevirtide-gmod [BLV]) for the treatment of chronic HDV infection and available data on finite treatment duration and outcomes after discontinuation of therapy.

Some data may be outside of the US FDA-approved prescribing information. In providing this data, Gilead Sciences, Inc. is not making any representation as to its clinical relevance or to the use of any Gilead product(s). For information about the approved conditions of use of any Gilead drug product, please consult the FDA-approved prescribing information.

**The full indication, important safety information, and boxed warnings are available at: [www.gilead.com/-/media/files/pdfs/medicines/hdv/hepcludex/hepcludex\\_pi](http://www.gilead.com/-/media/files/pdfs/medicines/hdv/hepcludex/hepcludex_pi).**

---

## Summary

### Product Labeling<sup>1</sup>

Severe acute exacerbations of HDV and HBV infection may occur after BLV is discontinued, especially in patients with cirrhosis, who may be at increased risk of more severe flares or progression to hepatic decompensation. Monitor hepatic function closely with both clinical and laboratory follow-up, including HBV DNA and HDV RNA viral load, for at least 6 months in patients who discontinue BLV. Resumption of antiviral therapy may be warranted.

BLV is indicated for the treatment of chronic HDV infection in adults without cirrhosis or with compensated cirrhosis.

This indication is approved under accelerated approval based on a decrease in HDV RNA and ALT normalization. An improvement in disease-related clinical outcomes has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

The recommended dosage in adults is BLV 8.5 mg once daily administered by SUBQ injection.

BLV should be continued as long as it is associated with a response to treatment. The optimal treatment duration is unknown.

In all patients, manage the underlying HBV infection as clinically appropriate.

If a dose is missed, that dose should be taken as soon as possible. However, if it is almost time for the next dose, skip the missed dose and resume the original schedule.

The efficacy of BLV once daily in the treatment of adults with chronic HDV infection without cirrhosis or with compensated cirrhosis is based on data through Week 144 from a multicenter, randomized, open-label, parallel-arm phase 3 trial, Trial MYR301 (NCT03852719), in which 100 participants received BLV 8.5 mg once daily. The MYR301

protocol specified the BLV dose as 10 mg; however, a dose recovery study later showed that the delivered dose was 8.5 mg.

### Clinical Data: BLV Treatment Duration and Discontinuation of Therapy

In the phase 2b MYR204 study that evaluated BLV and PEG-IFN $\alpha$  treatment alone and in combination in participants with chronic HDV (N=174), undetectable HDV RNA levels 48 weeks after stopping treatment were observed in 26% of participants in the BLV 2 mg + PEG-IFN $\alpha$  arm, 12% in the BLV 10 mg arm, 46% in the BLV 10 mg + PEG-IFN $\alpha$  arm, and 25% in the PEG-IFN $\alpha$  arm. Safety results through Week 144 are reported below.<sup>2</sup>

- In participants with undetectable HDV RNA levels at EOT in the BLV + PEG-IFN $\alpha$  arms, treatment with BLV 10 mg ( $P\leq 0.04$ ), HDV RNA levels <median ( $P=0.0003$ ), and liver stiffness values <11.1 kPa ( $P=0.02$ ) were baseline predictors of maintaining undetectable HDV RNA levels at 48 weeks after EOT.<sup>3</sup> On-treatment predictors of undetectable HDV RNA 48 weeks after EOT included undetectable HDV RNA at Week 24, Week 48, and EOT.<sup>3,4</sup>

In the phase 3 MYR301 study that evaluated the safety and efficacy of BLV (2 mg, 10 mg, or 10 mg after a 48-week delay of treatment) in participants with chronic HDV (N=150), nearly half of participants who received BLV for 144 weeks and had undetectable HDV RNA at EOT sustained undetectability at 96 weeks after EOT. Across all treatment arms, rates of combined response, ALT normalization, and virologic response were similar at EOT and decreased from EOT to 96 weeks after EOT.<sup>5</sup>

- Across all treatment arms, 90% of participants with  $\geq 96$  weeks of continuous undetectable levels of HDV RNA at EOT sustained undetectable levels after EOT. Most relapses (93%) occurred within 24 weeks after EOT, and all relapses occurred within 48 weeks after EOT.<sup>5</sup>
- A univariate logistic regression analysis showed that being treated with BLV 10 mg or having an HDV RNA or HBsAg level below the median was predictive of undetectable levels of HDV RNA at EOT. On-treatment predictors of sustained undetectable levels of HDV RNA up to 48 weeks after EOT included early and long durations of on-treatment undetectable levels of HDV RNA.<sup>6</sup>

Two pooled analyses of data from participants from MYR204 and MYR301 were performed.<sup>7,8</sup>

- In one pooled analysis, treatment with BLV 10 mg + PEG-IFN $\alpha$  or BLV 10 mg for 144 weeks (vs 96 weeks) was associated with higher rates of undetectable HDV RNA at EOT and up to 48 weeks after EOT.<sup>7</sup>
- In an additional pooled analysis, almost half of participants with undetectable HDV RNA at EOT with BLV monotherapy or in combination with PEG-IFN $\alpha$  continued to have undetectable HDV RNA levels and maintained normal ALT levels through FU Week 48. Most participants with low-viremic relapse after EOT maintained normal ALT levels through FU Week 48, whereas the rate of ALT normalization decreased over time in participants with high viremic relapse after EOT. Almost half of participants who had undetectable HDV at EOT remained virus free during FU. Among participants with virologic relapse, some maintained stability in markers of liver damage.<sup>8</sup>

In the D-SOLVE BUL-STOP trial, which assessed outcomes of participants who had received BLV for HDV treatment and discontinued with HDV RNA <LLOQ, 11/18 participants relapsed. Participants who relapsed had a longer median time to first undetectable HDV RNA after BLV initiation than did patients who did not relapse (76 and 24 weeks, respectively).<sup>9</sup>

### Real-World Data: BLV Treatment Duration and Discontinuation of Therapy

In a study that used data from the HEPDELTA cohort to assess factors associated with SVR at FU Week 24 after stopping BLV treatment, more patients who had undetectable HDV RNA for  $\geq 96$  weeks at EOT achieved SVR than patients who had undetectable HDV RNA for  $< 96$  weeks at EOT in the BLV monotherapy group ( $n/N=5/6$  [83%] and  $n/N=12/20$  [60%], respectively) and in the BLV + early IFN group ( $n/N=8/12$  [67%] and  $n/N=20/37$  [54%]).<sup>10</sup>

An analysis of the multicenter French BuleDelta cohort study examined SVR rates and factors associated with maintaining SVR in 34 patients with chronic HDV who stopped BLV 2 mg  $\pm$  PEG-IFN $\alpha$  after achieving undetectable HDV RNA levels (mean [SD] duration of treatment was 17.7 [8.8] months). The SVR rate was 47.1% (16/34) at post-treatment Week 96. Of the 18 patients who experienced a virological relapse, 55.6% (10/18) did so within 12 weeks of stopping treatment. No baseline demographics or clinical characteristics were found to be associated with SVR.<sup>11</sup>

---

## Clinical Data: BLV Treatment Duration and Discontinuation of Therapy


### MYR204 Phase 2b Study

#### Study design and demographics<sup>2</sup>

The MYR204 study was a multicenter, open-label, randomized, phase 2b study conducted in four countries (ie, France, Russia, Romania, and Moldova) that evaluated the safety and efficacy of BLV (10 mg or 2 mg subcutaneously once daily; each dosed for 96 weeks) and PEG-IFN $\alpha$  (180 mcg/week; dosed for 48 weeks) alone and in combination in 174 participants with chronic HDV. Participants were randomly assigned to one of four treatment arms, as shown in Figure 1.

The primary endpoint was defined as undetectable ( $< \text{LLOQ}$ ) HDV RNA 24 weeks after EOT (Week 120), and the primary efficacy analysis assessed the difference in outcomes between the BLV 10 mg + PEG-IFN $\alpha$  arm and the BLV 10 mg monotherapy arm. Additional endpoints evaluated 48 weeks after EOT included undetectable HDV RNA, ALT normalization, the proportion of participants who had a composite response (undetectable HDV RNA and ALT normalization), liver stiffness changes from baseline, and safety.

**Figure 1. MYR204: Study Design<sup>2</sup>**



<sup>a</sup>One participant withdrew consent and was excluded from the analysis.

**Table 1. MYR204: Baseline Demographics and Disease Characteristics<sup>2</sup>**


Key Demographics and Characteristics		BLV 2 mg + PEG-IFN $\alpha$ (n=50)	BLV 10 mg (n=50)	BLV 10 mg + PEG-IFN $\alpha$ (n=50)	PEG-IFN $\alpha$ (n=24)
Age, mean (SD), years		41 (9.3)	40 (8.5)	41 (8.6)	41 (8.4)
Male, n (%)		33 (66)	38 (76)	35 (70)	18 (75)
Race, <sup>a</sup> n (%)	White	44 (88)	44 (88)	43 (86)	20 (83)
	Asian	3 (6)	4 (8)	4 (8)	4 (17)
	Black	3 (6)	2 (4)	2 (4)	0
Cirrhosis, n (%)		17 (34)	17 (34)	17 (34)	8 (33)
Liver stiffness, median (IQR), kPa		10.7 (7.8–16.5)	10.8 (8.5–14.1)	10.5 (7.8–14.3)	12.2 (8.6–18.9)
ALT level, median (IQR), U/L		81 (56–143)	90 (63–127)	82 (55–117)	91 (64–152)
HDV RNA, median (IQR), log <sub>10</sub> IU/mL		5.6 (4.3–6.3)	5.6 (4.6–6.3)	5.5 (4.4–6.1)	5.2 (4.6–5.8)
HDV, GT 1/5/6, n (%)		48 (96)/1 (2)/1 (2)	49 (98)/1 (2)/0	47 (94)/2 (4)/0	24 (100)/0/0
HBsAg, mean (SD), log <sub>10</sub> IU/mL		3.7 (0.6)	3.7 (0.6)	3.7 (0.7)	3.6 (0.5)
Prior IFN use, n (%)		25 (50)	21 (42)	26 (52)	12 (50)
Concomitant HBV treatment, n (%)		24 (48)	23 (46)	25 (50)	11 (46)

<sup>a</sup>Other race (not specified) in the BLV 10 mg + PEG-IFN $\alpha$  arm (n=1).

## Efficacy results: SVR up to Week 48 after stopping treatment


The proportions of participants with undetectable HDV RNA at EOT and through Week 48 after EOT are presented in Figure 2. Participants who had received BLV 10 mg + PEG-IFN $\alpha$  had the highest rates of undetectable HDV RNA after stopping treatment; these rates were maintained at 46% from Weeks 24 to 48. In general, rates of undetectable HDV RNA were maintained in all arms from Weeks 24 to 48 after stopping therapy. At Week 24 after EOT, there were significantly higher rates of undetectable HDV RNA with BLV 10 mg + PEG-IFN than with BLV 10 mg (between-group difference, 34%; 95% CI: 15–50%;  $P < 0.001$ ).<sup>2</sup>

**Figure 2. MYR204: Rates of Undetectable HDV RNA Through Post-Treatment Week 48 (Missing=Failure Analysis)<sup>2</sup>**




Rates of ALT normalization increased in all treatment arms over time; the highest rates of ALT normalization occurred in the arms that received PEG-IFNα (Figure 3).<sup>2</sup>

**Figure 3. MYR204: Rates of ALT Normalization Through 48 Weeks After EOT by Treatment Arm (Missing=Failure Analysis)<sup>2</sup>**



The BLV 10 mg + PEG-IFNα arm had higher rates of composite response (undetectable HDV RNA and ALT normalization) than the other arms (Figure 4).<sup>2</sup>

**Figure 4. MYR204: Composite Response<sup>a</sup> Rates Through 48 Weeks After EOT (Missing=Failure Analysis)<sup>2</sup>**



<sup>a</sup>Composite response was defined as undetectable HDV RNA and ALT normalization.

From baseline through 48 weeks after EOT, BLV was associated with reductions in liver stiffness, with least squares mean changes from baseline of -2.4 kPa in the

BLV 2 mg + PEG-IFN $\alpha$  arm, -0.8 kPa in the BLV 10 mg arm, -2.5 kPa in the BLV 10 mg + PEG-IFN $\alpha$  arm, and -0.3 kPa in the PEG-IFN $\alpha$  monotherapy arm.<sup>12</sup>

At 48 weeks after EOT, HBsAg loss was observed with BLV + PEG-IFN $\alpha$  (Table 2).<sup>12</sup>

**Table 2. MYR204: HBsAg Changes at 48 Weeks After EOT by Treatment Arm (Missing=Failure Analysis)<sup>2,12</sup>**

HBsAg Outcomes	BLV 2 mg + PEG-IFN $\alpha$ (n=50)	BLV 10 mg (n=50)	BLV 10 mg + PEG-IFN $\alpha$ (n=50)	PEG-IFN $\alpha$ (n=24)
HBsAg $\geq 1$ log <sub>10</sub> IU/mL decrease, n (%)	11 (22)	2 (4)	8 (16)	4 (17)
HBsAg loss, n (%)	5 (10)	1 (2)	2 (4)	0
HBsAg seroconversion, n (%)	4 (8)	0	2 (4)	0
Change from baseline in HBsAg, mean (SD), log <sub>10</sub> IU/mL	n=34 -1.39 (1.847)	n=44 -0.24 (0.772)	n=43 -0.72 (1.072)	n=17 -0.51 (0.705)

## Safety results through Week 144

Overall, on-treatment safety outcomes were similar among the arms that received PEG-IFN $\alpha$ . Few Grade 3 to 4 AEs and no SAEs were related to BLV, and AEs led to discontinuation of study treatment at low rates (Table 3). One death was reported in the BLV 2 mg + PEG-IFN $\alpha$  arm secondary to anaplastic astrocytoma, which was deemed unrelated to study treatment.<sup>2</sup>

**Table 3. MYR204: On-Treatment Safety Outcomes<sup>2a</sup>**

AEs, n (%)	BLV 2 mg + PEG-IFN $\alpha$ (n=50)	BLV 10 mg (n=50)	BLV 10 mg + PEG-IFN $\alpha$ (n=50)	PEG-IFN $\alpha$ (n=24)
Any AE	49 (98)	42 (84)	50 (100)	22 (92)
Any Grade 3–4 AE related to BLV	2 (4)	0	2 (4)	N/A
Any Grade 3–4 AE related to PEG-IFN $\alpha$	26 (52)	N/A	26 (52)	13 (54)
Any SAE	3 (6)	2 (4)	8 (16)	3 (12)
Any SAE related to BLV	0	0	0	N/A
Any SAE related to PEG-IFN $\alpha$	2 (4)	N/A	1 (2)	1 (4)
Any BLV-related AE that led to discontinuation	1 (2)	1 (2)	1 (2)	N/A
Any PEG-IFN $\alpha$ -related AE that led to discontinuation	3 (6)	N/A	2 (4)	1 (4)

<sup>a</sup>Includes any AE reported from the date the trial drug was initiated through 30 days after discontinuation.

Post-treatment safety outcomes are presented in Table 4. One death was reported in the BLV 10 mg + PEG-IFN $\alpha$  arm secondary to esophageal varices hemorrhage. Most ALT/AST elevations were transient and asymptomatic and were associated with HDV RNA rebounds.<sup>2</sup>

**Table 4. MYR204: Post-Treatment Safety Outcomes<sup>12</sup>**

AEs, n (%)	BLV 2 mg + PEG-IFN $\alpha$ (n=50)	BLV 10 mg (n=50)	BLV 10 mg + PEG-IFN $\alpha$ (n=50)	PEG-IFN $\alpha$ (n=24)
Any AE	28 (56)	34 (68)	29 (58)	19 (79)
Any Grade $\geq 3$	4 (8)	11 (22)	10 (20)	2 (8)
Any SAE	2 (4)	4 (8)	4 (8)	1 (4)
Any SAE related to BLV	1 (2)	1 (2)	1 (2)	N/A
Any hepatic AE	8 (16)	19 (38)	10 (20)	4 (17)

AEs, n (%)		BLV 2 mg + PEG-IFN $\alpha$ (n=50)	BLV 10 mg (n=50)	BLV 10 mg + PEG-IFN $\alpha$ (n=50)	PEG-IFN $\alpha$ (n=24)
Hepatic AEs occurring in >1 participant	ALT increased	8 (16)	14 (28)	5 (10)	3 (13)
	AST increased	7 (14)	11 (22)	5 (10)	1 (4)
	GGT increased	1 (2)	5 (10)	1 (2)	1 (4)
	Bilirubin increased <sup>a</sup>	0	5 (10)	3 (6)	0
	Jaundice	0	2 (4)	0	0
	Prothrombin level decreased	0	1 (2)	1 (2)	0
	Ascites	0	0	0	1 (4)
	Alkaline phosphatase increased	0	0	0	1 (4)
	HDV	0	0	1 (2)	0
	Hepatic failure <sup>b</sup>	0	0	1 (2)	0

<sup>a</sup>Included the following terms: bilirubin conjugated increased, blood bilirubin increased, hyperbilirubinemia, and urobilinogen urine increased.


<sup>b</sup>Reported as chronic liver insufficiency.

## Subanalysis: predictors of post-treatment SVR<sup>4</sup>

An analysis of MYR204 examined HDV RNA levels <LLOQ reported as target not detected (undetectable HDV RNA) and HDV RNA levels <LLOQ reported as target detected (low-positive viremia) at EOT as predictors of SVR up to Week 48 after stopping treatment. Similar to the previous study, participants who had received BLV 10 mg + PEG-IFN $\alpha$  had the highest rates of HDV RNA <LLOQ (which included undetectable and low-positive HDV RNA) at EOT and after stopping treatment, and in general, within each treatment arm, the proportions of participants with HDV RNA levels <LLOQ remained stable from post-treatment Weeks 24 to 48.

Overall, most participants (73%; 24/33) who had low-positive viremia at EOT had experienced viral rebound (HDV RNA  $\geq$ LLOQ) 48 weeks after stopping treatment; in contrast, most participants (60%; 44/73) who had undetectable HDV RNA at EOT continued to have undetectable levels at 48 weeks (Figure 5).

**Figure 5. MYR204: HDV RNA Status 48 Weeks After Stopping Treatment According to Viremic Status<sup>a</sup> at EOT<sup>4</sup>**



<sup>a</sup>Undetectable HDV RNA was defined as an HDV RNA level <LLOQ and target not detected. Low-positive viremia was defined as an HDV RNA level <LLOQ and target detected.

The 2 participants with low-positive viremia at EOT who had undetectable HDV RNA levels at 48 weeks post treatment had both received combination treatment with BLV (2 mg [n=1] or 10 mg [n=1]) and PEG-IFN $\alpha$ . Approximately half of the participants (15/33; 45%) with

low-positive viremia at EOT were receiving BLV 10 mg as monotherapy, and all 15 either experienced viral rebound (n=13) or had low-positive viremia (n=2) at Week 48 post-BLV treatment. Of the 44 participants (60%) with undetectable HDV RNA levels at EOT and at Week 48 post treatment, most (33/44; 75%) had received BLV + PEG-IFN $\alpha$  treatment.

### **Subanalysis: predictors of post-treatment response<sup>3</sup>**

A subanalysis of MYR204 was conducted to identify baseline characteristics or characteristics of viral kinetics during treatment that predicted EOT or post-treatment response in the pooled BLV 2 mg and 10 mg + PEG-IFN $\alpha$  combination treatment arms (n=100). A logistic regression analysis was used to evaluate the association between clinical characteristics and response at EOT and post-treatment Weeks 24 and 48. Viral kinetics were evaluated in a subset of participants (n=51) with undetectable HDV RNA levels at EOT to identify whether any characteristics were associated with maintaining undetectable levels after stopping therapy.

The strongest on-treatment predictors of having undetectable levels of HDV RNA at 48 weeks after EOT included achieving undetectable HDV RNA by treatment Week 24 (OR, 13.5; 95% CI: 4.6–40;  $P<0.0001$ ) or Week 48 (OR, 13.7; 95% CI: 4.2–45;  $P<0.001$ ). Baseline characteristics that were key predictors of undetectable HDV RNA levels 48 weeks after EOT included the following:

- Treatment with BLV 10 mg (vs 2 mg): OR, 2.4; 95% CI: 1.1–5.6;  $P\leq 0.04$
- Lower HDV RNA levels (<median vs  $\geq$ median [median: 5.54 log<sub>10</sub> IU/mL]: OR, 5.6; 95% CI: 2.2–14.3;  $P=0.0003$ )
- Lower liver stiffness measurement values (<11.1 vs  $\geq$ 11.1 kPa: OR, 2.9; 95% CI: 1.2–7;  $P=0.02$ ).

Among the 51 participants in the combination therapy arms with undetectable HDV RNA levels at EOT, a baseline HDV RNA level below the median (5.09 log<sub>10</sub> IU/mL) was a significant predictor of not having a viral relapse 48 weeks after EOT (OR, 4; 95% CI: 1.2–13.9;  $P=0.03$ ). Shorter time to onset of undetectable HDV RNA levels (OR, 0.9; 95% CI: 0.9–0.9;  $P=0.003$ ) and longer duration of undetectable HDV RNA on treatment (OR, 1.01; 95% CI: 1–1.01;  $P=0.0029$ ) were also associated with no viral relapse 48 weeks after stopping BLV among participants with undetectable HDV RNA at EOT. Participants who had undetectable HDV RNA at on-treatment Week 24 had a high likelihood of maintaining undetectable HDV RNA levels at Week 48 (n/N, 23/25; OR, 19.1; 95% CI: 3.6–100.8;  $P=0.0005$ ).

### **Subanalysis: correlation analysis of intrahepatic and serological response<sup>13</sup>**

An analysis of MYR204 examined correlations between changes in intrahepatic and serum parameters, including correlations between intrahepatic and serum HDV RNA levels, though the study was not powered for this analysis. Evaluable paired biopsies (baseline and 24 weeks after EOT) were obtained from 42 participants for evaluation of intrahepatic HDV and HBV RNA and from 50 participants for evaluation of HDAg status.

Intrahepatic HDV RNA levels decreased from baseline to 24 weeks after EOT in all treatment arms. The largest decrease after treatment stopped was observed in the BLV 10 mg + PEG-IFN $\alpha$  arm. Intrahepatic HDV RNA levels at post-treatment Week 24 were <LLOQ in 73% of participants (8/11) in the BLV 10 mg + PEG-IFN $\alpha$  arm (median change: -3.16 log<sub>10</sub>;  $P\leq 0.01$ ), 57% (8/14) in the BLV 2 mg + PEG-IFN $\alpha$  arm (median change:

-1.99 log<sub>10</sub>;  $P \leq 0.05$ ), 8% (1/12) in the BLV 10 mg arm (median change: -0.76 log<sub>10</sub>), and 60% (2/5) in the PEG-IFN $\alpha$  arm (median change: -1.94 log<sub>10</sub>).

Similarly, the proportions of HDAg+ cells in the liver decreased from baseline to post-treatment Week 24 in all treatment arms; the largest decrease after treatment stopped was observed in the BLV 10 mg + PEG-IFN $\alpha$  arm. HDAg+ liver cells at post-treatment Week 24 were <LLOQ in 67% of participants (8/11) in the BLV 10 mg + PEG-IFN $\alpha$  arm (median change: -1.85 log<sub>10</sub>;  $P \leq 0.05$ ), 44% (8/14) in the BLV 2 mg + PEG-IFN $\alpha$  arm (median change: -0.98 log<sub>10</sub>;  $P \leq 0.05$ ), 8% (1/13) in the BLV 10 mg arm (median change: -0.77 log<sub>10</sub>), and 67% (4/6) in the PEG-IFN $\alpha$  arm (median change: -1.87 log<sub>10</sub>).


Correlation analyses found a strong relationship ( $P < 0.0001$ ) between intrahepatic HDV RNA levels and HDAg+ cell numbers, which suggests that treatment with BLV resulted in fewer HDV-infected cells. Similarly, levels of HDV RNA in the serum were correlated with levels in the liver ( $P = 0.0027$ ). Changes in intrahepatic levels of HDV RNA from baseline to post-treatment Week 24 mirrored the changes observed in serum levels ( $P < 0.0001$ ); similarly, changes in intrahepatic HDV RNA levels mirrored the number of HDAg+ cells ( $P < 0.0001$ ), which could indicate that BLV treatment decreased the number of HDV-infected cells.

Analyses of intrahepatic HBV RNA did not find significant changes from baseline to post-treatment Week 24 in any of the treatment arms. Among select participants in the BLV 10 mg and 2 mg + PEG-IFN $\alpha$  arms, undetectable HDV RNA levels were observed and were maintained after they stopped treatment, with no reduction in HBsAg.

## MYR301 Phase 3 Study

### Study design and demographics

MYR301 was an open-label, multicenter, randomized, phase 3 study conducted in four countries (Germany, Italy, Russia, and Sweden) that evaluated the safety and efficacy of BLV 2 mg or 10 mg for 48 weeks compared with delayed treatment in participants with chronic HDV infection (N=150). After 48 weeks, participants in the delayed treatment arm received BLV 10 mg for 96 weeks; all treatment arms were followed after EOT (Figure 6). The primary endpoint was the combined response of undetectable (<LLOD) HDV RNA or a decrease of  $\geq 2$  log<sub>10</sub> IU/mL from baseline and ALT level normalization. Safety and efficacy endpoints were assessed at EOT (Week 144) and at 48 weeks (Week 192) and 96 weeks (Week 240) after EOT.<sup>5</sup>



Abbreviations: FU24/48=follow-up 24/48 weeks after EOT; SUBQ=subcutaneous(ly).

<sup>a</sup>The MYR301 protocol specified the dose as 10 mg per vial, and the delivered dose was 8.5 mg.

Approximately half of participants in each treatment arm had cirrhosis at baseline, and demographics and disease characteristics were well balanced across all arms (Table 5).<sup>5</sup>

**Table 5. MYR301: Baseline Demographics and Disease Characteristics<sup>5</sup>**

Key Demographics and Characteristics		Delayed Treatment BLV 10 mg (n=51 <sup>a</sup> )	BLV 2 mg (n=49)	BLV 10 mg (n=50)
Age, mean (SD), years		41 (8)	44 (9)	41 (9)
Male, n (%)		26 (51)	30 (61)	30 (60)
Race, <sup>b</sup> n (%)	White	40 (78)	41 (84)	43 (86)
	Asian	11 (22)	8 (16)	6 (12)
Cirrhosis, n (%)		24 (47)	23 (47)	24 (48)
Liver stiffness, mean (SD), kPa		15.3 (9)	14 (8.2)	14.8 (9.3)
ALT level, mean (SD), U/L		102 (62)	108 (63)	123 (81)
HDV RNA, mean (SD), log <sub>10</sub> IU/mL		5.08 (1.36)	5.1 (1.19)	4.96 (1.46)
HDV GT 1, <sup>c</sup> n (%)		51 (100)	49 (100)	48 (96)
HBsAg, mean (SD), log <sub>10</sub> IU/mL		3.68 (0.47)	3.67 (0.52)	3.61 (0.59)
HBV DNA, mean (SD), log <sub>10</sub> IU/mL		0.89 (0.99)	1.31 (1.28)	1.08 (1.26)
HBV GT A/D, <sup>d</sup> n (%)		2 (4)/44 (86)	2 (4)/47 (96)	2 (4)/44 (88)
Previous IFN therapy, n (%)		29 (57)	26 (53)	29 (58)
Concomitant HBV NUC treatment, n (%)		33 (65)	32 (65)	27 (54)
Initiated prior to baseline		30 (59)	27 (55)	25 (50)

<sup>a</sup>One participant from the delayed BLV 10 mg arm withdrew after randomization and before receiving BLV and was not included in efficacy and safety analyses.

<sup>b</sup>Black race in the BLV 10 mg arm (n=1).


<sup>c</sup>In the BLV 10 mg arm: HDV GT 5 (n=1), missing HDV GT data (n=1).

<sup>d</sup>In the BLV 10 mg arm: no data (n=3), HBV GT E (n=1). In the delayed treatment BLV 10 mg arm: no data (n=3), unclassified HBV GT (n=2).

## Efficacy results at EOT and at 48 and 96 weeks after EOT<sup>5</sup>

At Week 240 (96 weeks after EOT), response rates across all efficacy outcomes were sustained between 48 and 96 weeks after EOT (Figure 7, Figure 8, Figure 9).

**Figure 7. MYR301: Combined Response Rates (Virologic Response<sup>a</sup> and ALT Normalization<sup>b</sup>) at EOT and at 48 and 96 Weeks After EOT<sup>5</sup>**




<sup>a</sup>Defined as an undetectable (<LLOD) HDV RNA or a decrease of  $\geq 2$  log<sub>10</sub> IU/mL from baseline.

<sup>b</sup>Defined at Russian sites as  $\leq 31$  U/L for females and  $\leq 41$  U/L for males; at all other sites, it was defined as  $\leq 34$  U/L for females and  $\leq 49$  U/L for males.

<sup>c</sup>Included 1 participant who restarted BLV before the visit.

**Figure 8. MYR301: Virologic Response<sup>a</sup> at EOT and at 48 and 96 Weeks After EOT<sup>5</sup>**




<sup>a</sup>Defined as an undetectable (<LLOD) HDV RNA or a decrease of  $\geq 2 \log_{10}$  IU/mL from baseline.

<sup>b</sup>Included 2 participants who restarted BLV before the visit.

<sup>c</sup>Included 1 participant who restarted BLV before the visit.

<sup>d</sup>Quantified using RoboGene version 2.0, which has an LLOD of 6 IU/mL.

**Figure 9. MYR301: ALT Normalization<sup>a</sup> at EOT and at 48 and 96 Weeks After EOT<sup>5</sup>**




<sup>a</sup>Defined at Russian sites as  $\leq 31$  U/L for females and  $\leq 41$  U/L for males; at all other sites, it was defined as  $\leq 34$  U/L for females and  $\leq 49$  U/L for males.

<sup>b</sup>Included 1 participant who restarted BLV before the visit.

<sup>c</sup>Included 2 participants who restarted BLV before the visit.

At 96 weeks after EOT, 21% of participants overall had undetectable levels of HDV RNA (Figure 10). Across all arms, 65/149 participants (44%) had undetectable levels of HDV RNA at EOT; of those with FU data, 23/64 participants (36%) sustained undetectable levels through 96 weeks after EOT. Across all treatment arms, 90% of participants with  $\geq 96$  weeks of continuous undetectable levels of HDV RNA at EOT sustained undetectable levels after EOT. Most relapses (93%) occurred within 24 weeks after EOT, and all relapses occurred within 48 weeks after EOT.

**Figure 10. MYR301: Undetectable HDV RNA<sup>a</sup> at EOT and at 48 and 96 Weeks After EOT<sup>5</sup>**



<sup>a</sup>Quantified using RoboGene version 2.0, with an LLOD of 6 IU/mL.

Note: Some participants with undetectable levels of HDV RNA at 96 weeks after EOT had low-level viremia or transient virologic relapses during FU.

## Predictors of undetectable HDV RNA at EOT and 48 weeks after EOT<sup>6</sup>

An analysis was conducted to evaluate baseline predictors of undetectable levels of HDV RNA at EOT (after 96 or 144 weeks of BLV monotherapy) and to identify predictors of sustained undetectable levels of HDV RNA up to 48 weeks after EOT. A univariate logistic regression analysis showed that being treated with BLV 10 mg or having an HDV RNA or HBsAg level below the median was predictive of undetectable levels of HDV RNA at EOT (Table 6).

**Table 6. MYR301: Baseline Predictors of Undetectable Levels of HDV RNA at EOT<sup>6</sup>**

Variable	Undetectable at EOT, %	Undetectable at EOT Reference, %	OR (95% CI); P-Value
BLV 10 mg (vs BLV 2 mg)	50	28.6	2.5 (1.1–5.7); 0.03
Delayed treatment 10 mg (vs BLV 2 mg)	52	28.6	2.7 (1.2–6.2); 0.02
HDV RNA <5.2 (vs ≥5.2) log <sub>10</sub> IU/mL	56.8	30.7	3.2 (1.6–6.5); 0.001
HBsAg <3.8 (vs ≥3.8) log <sub>10</sub> IU/mL	52.9	35.1	2.4 (1.2–4.8); 0.02

In participants with undetectable levels of HDV RNA at EOT, predictors of sustained undetectable levels up to 48 weeks after EOT included a baseline HDV RNA <4.6 log<sub>10</sub> IU/mL (OR, 8.2; 95% CI: 2.3–29.5; *P*=0.001) and lower levels of HBsAg per log<sub>10</sub> IU/mL (OR, 0.3; 95% CI: 0.1–0.8; *P*=0.019).

On-treatment predictors of sustained undetectable levels of HDV RNA up to 48 weeks after EOT included early and long durations of on-treatment undetectable levels of HDV RNA (Table 7).

**Table 7. MYR301: On-Treatment Predictors of Sustained Undetectable HDV RNA Levels up to 48 Weeks After EOT<sup>6</sup>**

Variable	Sustained Undetectable, %	Sustained Undetectable Reference, %	OR (95% CI); P-Value
Continuously undetectable HDV RNA at EOT	≥48 weeks (vs <48 weeks)	62.5	17.2 (4–75.1); 0.0001
	≥96 weeks (vs <96 weeks)	90	26.6 (2.7–262.4); <0.005

Variable		Sustained Undetectable, %	Sustained Undetectable Reference, %	OR (95% CI); P-Value
Duration of continuous undetectable HDV RNA at EOT per 24 weeks		-	-	2.9 (1.7–4.8); <0.0001
Undetectable HDV RNA (yes vs no)	Week 16	80	32.2	14.5 (1.3–156.9); 0.03
	Week 24	77.8	29.1	10.8 (1.8–64.8); 0.009
	Week 48	70.8	15	33.1 (5.9–186.9); <0.0001
	Week 72	57.1	10.3	20.3 (3.9–107); 0.0004

## Safety results at 96 weeks after EOT<sup>5</sup>

During treatment, 1 participant in the delayed BLV 10 mg arm developed nonserious ascites. Between EOT and 96 weeks after EOT, 1 case of ascites was reported in the delayed BLV 10 mg arm, 1 case each of bleeding from varices and hepatocellular carcinoma was reported in the BLV 2 mg arm, and 1 case of hepatic encephalopathy was reported in the BLV 10 mg arm. Post-treatment ALT flares (ALT >10 × ULN) were reported in 6, 5, and 3 participants in the delayed BLV 10 mg, BLV 2 mg, and BLV 10 mg arms, respectively; most occurred early and resolved. Most participants (55–60%) remained in the study through 96 weeks after EOT, and withdrawal of consent was the most common reason for study discontinuation.

## Pooled Analyses of MYR204 and MYR301

### Rates of undetectable HDV RNA at EOT and at 24 and 48 weeks after EOT<sup>Z</sup>

#### Study design and demographics

A pooled analysis of participants who completed 96 or 144 weeks of BLV 10 mg + PEG-IFN $\alpha$  in MYR204 or BLV 10 mg in MYR301 was conducted to assess whether undetectable levels of HDV RNA or low-level viremia (HDV RNA <50 IU/mL) at EOT affected post-treatment virologic response rates up to 48 weeks after EOT (Table 8).

**Table 8. Pooled Analysis of MYR204 and MYR301: Baseline Demographics and Disease Characteristics<sup>Z</sup>**


Key Demographics and Characteristics		BLV 10 mg 96W (n=100)	BLV 10 mg 144W (n=50)	BLV 10 mg + PEG-IFN $\alpha$ 96W (n=50)
Age, mean (SD), years		41 (8)	41 (8.5)	41 (8.6)
Male, n (%)		64 (64)	30 (60)	35 (70)
Race, <sup>a</sup> n (%)	White	83 (83)	43 (86)	43 (86)
	Asian	15 (15)	6 (12)	4 (8)
	Black	2 (2)	1 (2)	2 (4)
Cirrhosis, n (%)		41 (41)	24 (48)	17 (34)
Liver stiffness, mean (SD), kPa		14.4 (9.7)	14.8 (9.26)	12.5 (7.6)
ALT, mean (SD), U/L		100 (86.1)	123 (80.6)	113 (98.6)
HDV RNA, mean (SD), log <sub>10</sub> IU/mL		5.2 (1.36)	5 (1.46)	5.1 (1.34)
Prior IFN use, n (%)		50 (50)	29 (58)	26 (52)
Concomitant NUC use for HBV, n (%)		55 (55)	27 (54)	25 (50)

<sup>a</sup>Other race (not specified) in the BLV 10 mg + PEG-IFN $\alpha$  arm (n=1).

## Results

Treatment with BLV 10 mg + PEG-IFN $\alpha$  or BLV 10 mg for 144 weeks (vs 96 weeks) was associated with higher rates of undetectable HDV RNA at EOT and up to 48 weeks after EOT (Figure 11).

**Figure 11. Pooled Analysis of MYR204 and MYR301: Rates of Undetectable HDV RNA at EOT and at 24 and 48 Weeks After EOT<sup>Z</sup>**



Of the participants with undetectable HDV RNA at EOT, 35% of participants (13/37) in the BLV 10 mg for 96 weeks group, 44% (11/25) in the BLV 10 mg for 144 weeks group, and 60% (21/35) in the BLV 10 mg + PEG-IFN $\alpha$  group maintained undetectable HDV RNA at 48 weeks after EOT; however, of the participants with low-level viremia at EOT, undetectable HDV RNA was observed in 3%, 10%, and 13%, respectively, through 48 weeks after EOT. In participants with either undetectable HDV RNA or low-level viremia at EOT who had detectable levels at 48 weeks after EOT, HDV RNA levels returned to levels similar to those at pretreatment.

From EOT up to 48 weeks after EOT, ALT normalization rates were maintained in participants who had undetectable HDV RNA or low-level viremia at EOT (Table 9).

**Table 9. Pooled Analysis of MYR204 and MYR301: ALT Normalization Rates at 48 Weeks After EOT by Virologic Response at EOT<sup>Z</sup>**

HDV RNA Level at EOT	ALT Normalization, n/N (%)	
	EOT	48W After EOT <sup>a</sup>
Undetectable	68/97 (71)	38/49 (78)
<50 IU/mL	39/48 (81)	7/9 (78)
≥50 IU/mL	20/43 (47)	15/105 (14)

<sup>a</sup>Excluded participants who terminated the study early (n=37).

## Rates of undetectable HDV RNA at EOT and at 48 and 96 weeks after EOT<sup>8</sup>

### Study design and demographics

An additional pooled analysis of data from the MYR204 and MYR301 studies evaluated the durability of virologic response through 48 (Week 192) and 96 weeks (Week 240) after EOT in participants who had undetectable HBV DNA at EOT after they received BLV 2 mg or 10 mg for 96 or 144 weeks, either as monotherapy or combined with PEG-IFN $\alpha$ . Overall, 131 participants with FU data available were included (MYR204: BLV 2 mg + PEG-IFN $\alpha$ ,

n=21; BLV 10 mg + PEG-IFN $\alpha$ , n=35; BLV 10 mg, n=11; MYR301: BLV 2 mg, n=13; delayed BLV 10 mg, n=26; BLV 10 mg, n=25). Results were analyzed according to post-treatment outcome: sustained undetectable HDV RNA (n=57; defined as no positive HDV RNA test after EOT); low viremic relapse (n=14; defined as HDV RNA <50 IU/mL after EOT); high viremic relapse (n=60; defined as HDV RNA level of  $\geq$ 50 IU/mL after EOT).

Baseline demographics and characteristics were generally similar between participants who maintained undetectable rates of HDV RNA after EOT and those who relapsed after EOT (Table 10). Fewer of the participants who had high viremic relapse were male as compared with the proportion of those who had sustained undetectable HDV RNA or low viremic relapse.

**Table 10. Pooled Analysis of MYR204 and MYR301: Baseline Demographics and Disease Characteristics by Virologic Response Through FU Week 96<sup>a</sup>**


Key Demographics and Characteristics		Sustained Undetectable HDV RNA (n=57)	Low Viremic Relapse (n=14)	High Viremic Relapse (n=60)
Age, mean (SD), years		42.3 (8.9)	42.1 (10.7)	42.4 (7.5)
Male sex, n (%)		40 (70)	10 (71)	29 (48)
Race, <sup>a</sup> n (%)	White	48 (84)	13 (93)	50 (83)
	Asian	5 (9)	1 (7)	10 (17)
Cirrhosis, n (%)		20 (35)	5 (36)	20 (33)
Liver stiffness, mean (SD), kPa		12.2 (7.5)	12.6 (6.8)	13.2 (7.8)
ALT, mean (SD), U/L		106.1 (83.5)	117.1 (81.7)	95.3 (66.0)
HDV RNA, mean (SD), log <sub>10</sub> IU/mL		4.2 (1.6)	4.3 (1.6)	5.2 (1.2)
Prior IFN use, n (%)		29 (51)	6 (43)	36 (60)
Concomitant NUC use for HBV, n (%)		30 (53)	7 (50)	33 (55)

<sup>a</sup>Black/African American, n=3 and other race (not specified), n=1 in the undetectable HDV RNA arm.

## Results

During the FU period, a higher proportion of participants treated with BLV 2 or 10 mg + PEG-IFN $\alpha$  or BLV 2 or 10 mg as monotherapy for 144 weeks maintained sustained undetectable HDV RNA, compared with higher relapse rates observed after EOT in participants treated with BLV 10 mg for 96 weeks (Figure 12). A small proportion of participants in the overall cohort treated with BLV as monotherapy or BLV + PEG-IFN $\alpha$  progressed to low viremic relapse (Figure 12).

**Figure 12. Pooled Analysis of MYR204 and MYR301: Durability of Response After EOT by Treatment Arm<sup>8</sup>**



### ALT levels

Participants with sustained undetectable HDV RNA or low viremic relapse maintained rates of ALT level normalization after EOT through FU Week 48, whereas those with high viremic relapse showed reduced rates of ALT level normalization (Table 11).

**Table 11. Pooled Analysis of MYR204 and MYR301: ALT Level Normalization Through 48 Weeks After EOT by Relapse Category<sup>8</sup>**

Participants, n/N (%)	EOT	FU Week 4	FU Week 24	FU Week 48
Sustained Undetectable HDV RNA	44/57 (77)	47/57 (82)	48/57 (84)	42/57 (74)
Low Viremic Relapse	9/14 (64)	9/14 (64)	9/14 (64)	11/14 (79)
High Viremic Relapse	43/60 (72)	48/60 (80)	19/60 (32)	17/60 (28)

The mean changes in ALT levels from EOT to FU Week 48 in the sustained undetectable HDV RNA and low viremic relapse subgroups were 11.92 U/L and 7.36 U/L, respectively.

In the high viremic relapse subgroup, mean ALT levels increased from 32 U/L at EOT to 81 U/L at FU Week 24 and remained elevated through 48 weeks after EOT. The mean change in ALT levels from EOT to FU Week 48 was 47.41 U/L.

### Liver stiffness

Mean liver stiffness continued to decline after EOT in participants with sustained undetectable HDV RNA or low viremic relapse, whereas an increase was observed in participants who experienced high viremic relapse. The mean changes from EOT to FU Week 48 in the sustained undetectable HDV RNA and low viremic relapse subgroups were -0.56 kPa and -1.46 kPa, respectively, whereas the mean change in liver stiffness was +1.19 kPa in high viremic relapse subgroup.

## D-SOLVE BUL-STOP Trial<sup>9</sup>

### Study design and demographics

A multicenter study assessed outcomes of participants who had received BLV for HDV treatment up to 48 weeks after BLV discontinuation (N=18). Eligible participants were adults with HDV and compensated liver disease who had received BLV treatment for ≥48 weeks, had HDV RNA <100 IU/mL for ≥24 weeks while receiving BLV, had ALT level <1.5 × ULN,

and were receiving stable and continued NUC treatment. Baseline demographics are presented in Table 12.

**Table 12. D-SOLVE BUL-STOP: Baseline Demographics and Disease Characteristics<sup>9</sup>**

Key Demographics and Characteristics	BLV (N=18)
Male, n (%)	8 (44)
Age, median (range), years	57 (34–75)
ALT, median (range), IU/L	26 (14–39)
Bilirubin, median (range), mcml/L	9 (4–30)
GGT, median (range), U/L	17 (8–89)
LSM, median (range), kPa	7 (5–20)
HDV RNA <LLOQ, n (%)	18 (100)
Undetectable HDV RNA, n (%)	15 (83)
Duration of BLV treatment, median (range), weeks	144 (53–250)
Time to first undetectable HDV RNA after BLV initiation, median (range), weeks	49 (7–117)

## Results

At data cutoff (April 31, 2026), 11 participants had relapsed (HDV RNA >100 IU/mL), and BLV was reinitiated in 10 of those participants after 65 to 329 days; the remaining participant withdrew consent. In the 11 participants who relapsed, the median (range) duration of BLV treatment was 158 (88–250) weeks, and the median (range) time to first undetectable HDV RNA after BLV initiation was 76 (24–117) weeks.

At Week 36 after BLV discontinuation, 7 participants had not relapsed, and Week 48 data was ongoing in 2 participants who showed no signs of relapse. In the 7 participants without relapse, the median (range) duration of BLV treatment was 100 (53–218) weeks, and the median (range) time to first undetectable HDV RNA after BLV initiation was 24 (7–60) weeks. Of the 6 participants who achieved first undetectable HDV RNA within 25 weeks of BLV initiation, 5 maintained virologic control after BLV discontinuation; however, all participants with a median time to first undetectable HDV RNA of >76 weeks relapsed. Of the 6 participants who achieved undetectable HDV RNA between 26 and 75 weeks, 4 relapsed.

---

## Real-World Data: BLV Treatment Duration and Discontinuation of Therapy

### French HEPDELTA Cohort Study<sup>10</sup>

#### Study design and demographics

A study using data from the HEPDELTA cohort assessed factors associated with SVR (undetectable HDV RNA at FU Week 24) in patients who received BLV ± IFN for HDV and had undetectable HDV RNA at EOT, including the impact of 96 weeks of undetectability while receiving BLV. Baseline demographics are presented in Table 13.

**Table 13. HEPDELTA Cohort: Baseline Demographics and Disease Characteristics<sup>10</sup>**

Key Demographics and Characteristics	Total (N=364)	BLV Monotherapy (n=163)	BLV + Early IFN (n=164)	BLV + Late IFN (n=37)
Age, mean ± SD, years	42.4±11.3	43.1±11.3	41.3±11.1	43.9±12.1
Male, n (%)	66.5	66.9	65.9	67.6
Cirrhosis, n (%)	67	66.9	65.9	73
Initial HDV RNA, mean ± SD, log IU/mL	5.88±1.42 <sup>a</sup>	5.59±1.38	6.06±1.48	6.36±1
LSM, mean ± SD, kPa	14.61±10.15 <sup>b</sup>	16.02±11.46	13.19±9.19	19.42±7.6
BLV treatment duration, mean ± SD, weeks	113.5±72.7 <sup>c</sup>	111.4±67.9	107±73.7	150.7±78.4
Discontinuation of treatment, n (%)	208 (57)	88 (54)	101 (61)	19 (51)
Undetectable HDV RNA at EOT, n/N (%)	79/208 (38) <sup>c</sup>	26/88 (29.5)	49/101 (48.5)	4/19 (21.1)

<sup>a</sup>P=0.0006. <sup>b</sup>P=0.04. <sup>c</sup>P=0.007.

## Results

In the BLV monotherapy group, 50%, 75%, and 83% of patients with durations of HDV RNA undetectability <48 weeks, ≥48 to <96 weeks, and ≥96 weeks, respectively, achieved SVR ( $P=0.0497$ ) compared with 44%, 71%, and 67% of patients in the BLV + early IFN group ( $P=0.186$ ). More patients who had undetectable HDV RNA for ≥96 weeks at EOT achieved SVR than did patients who had undetectable HDV RNA for <96 weeks at EOT in the BLV monotherapy group (n/N=5/6 [83%] and n/N=12/20 [60%], respectively) and in the BLV + early IFN group (n/N=8/12 [67%] and n/N=20/37 [54%]). One patient with cirrhosis in the BLV monotherapy group relapsed after 168 weeks of undetectable HDV RNA at FU Week 24, and 4 patients with cirrhosis in the BLV + early IFN group relapsed after a range of 96 to 192 weeks of undetectable HDV RNA at FU Weeks 12 or 24. In the BLV + late IFN group, no patients who had undetectable HDV RNA for <96 weeks and 1 patient who had undetectable HDV RNA for ≥96 weeks at EOT achieved SRV.

In a univariate analysis of factors associated with SVR in patients with undetectable HDV RNA at EOT, no factors were associated with SVR in the BLV monotherapy group, and duration of HDV RNA undetectability was associated with SVR at FU Week 48 in the BLV + early IFN group ( $P=0.0296$ ).

## French Multicenter Cohort Study (BuleDelta)<sup>11</sup>

### Study design and demographics

An analysis of the multicenter French BuleDelta real-world cohort examined the rates of SVR and the factors associated with maintaining SVR (persistently undetectable or unquantifiable HDV RNA) after stopping BLV treatment in patients with chronic HDV. A total of 34 patients who were treated with BLV 2 mg ± PEG-IFN $\alpha$  for a mean (SD) of 17.7 (8.8) months and had undetectable HDV RNA levels upon discontinuing antiviral treatment were included in the analysis.


**Table 14. BuleDelta Real-World Cohort: Baseline Demographics and Disease Characteristics<sup>11</sup>**

Key Demographics and Characteristics		All Patients (n=34)	BLV 2 mg (n=12)	BLV 2 mg + PEG-IFN $\alpha$ (n=22)
Age, mean (SD), years		44.1 (11.4)	42.1 (10.8)	45.1 (11.8)
Male, %		50	75	36.4
Ethnicity, %	Sub-Saharan African	50	41.7	54.5
	European	32.4	50	22.7
	Asian	14.7	8.3	18.2
	Other	2	0	4.5
Cirrhosis, %		76.5	66.7	81.8
FibroScan, mean (SD), kPa		11.9 (7.4)	13.2 (9.9)	11 (5.5)
ALT level, mean (SD), IU/L		91.3 (69.7)	97.5 (89.9)	87.8 (57.4)
HDV RNA, mean (SD), log <sub>10</sub> IU/mL		5.8 (1.3)	5.3 (1.5)	5.9 (1.1)
HDV, GT 1/5, %		69.6/30.4	75/25	66.7/33.3
HBsAg at inclusion, mean (SD), log <sub>10</sub> IU/mL		10,219 (15,653)	11,000 (18,803)	9772.4 (14,312)
NUC treatment at inclusion, %		97.1	91.7	100
Duration of BLV, mean (SD), months		17.7 (8.8)	18.9 (9.2)	17 (8.7)

## Results

At Week 96 of FU, the SVR rate was 47.1% (16/34). The overall virological relapse rate (ie, the proportion of patients with quantifiable HDV RNA) over 96 weeks of post-treatment FU was 52.9% (18/34); relapse rate by week is shown Figure 13.

**Figure 13. BuleDelta Real-World Cohort: Proportion of Patients With Virological Relapse Through FU Week 96 After Stopping BLV  $\pm$  PEG-IFN $\alpha$ <sup>11</sup>**



A number of factors (sex, duration of BLV treatment, treatment with PEG-IFN $\alpha$ , baseline HDV RNA level, presence of cirrhosis, normal ALT level at EOT, HBsAg levels at baseline and EOT, time to stopping BLV after initial undetectable HDV RNA, and time to first undetectable HDV RNA after initiation of BLV) were analyzed to determine if any were associated with virological relapse at Week 48 after stopping BLV; of these, only the time to first undetectable HDV RNA was significantly associated with virological relapse (univariate analysis OR, 1.08; 95% CI: 1.01–1.15;  $P=0.0161$ ), but this association was no longer statistically significant upon multivariate analysis.

A comparison of baseline demographics and clinical characteristics (including concomitant antiviral treatment, duration of BLV treatment, HDV RNA level, HDV GT, time between the first unquantifiable HDV RNA and discontinuation of BLV, and time between BLV initiation

and first unquantifiable HDV RNA) between patients who experienced early virological relapse (by post-treatment Week 12) and those who experienced virological relapse between Weeks 13 and 36 did not find any significant differences. Similarly, none of these factors were found to be significantly associated with SVR.

Safety data were not reported.

---

## References

1. Enclosed. Gilead Sciences Inc. HEPCLUDEX® (bulevirtide-gmod) injection, for subcutaneous use. US Prescribing Information. Foster City, CA.
2. Asselah T, Chulanov V, Lampertico P, et al. Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D. *N Engl J Med*. 2024;391(2):133-143.
3. Aleman S, Brunetto M, Blank A, et al. Efficacy and Safety of Bulevirtide Monotherapy for Chronic Hepatitis Delta: Posttreatment Results Through 48 Weeks After the End of Treatment From an Interim Analysis of a Randomized Phase 3 Study, MYR301 [Poster 1147]. Paper presented at: The Liver Meeting, American Association for the Study of Liver Diseases (AASLD); November 15-19, 2024; San Diego, CA.
4. Zoulim F, Asselah T, Chulanov V, et al. Undetectable HDV RNA Defined as Target Not Detected at the End of Treatment With Bulevirtide and/or Pegylated Interferon Alpha-2a Is an Important Predictor of 48 Weeks Sustained Virologic Response in Chronic Hepatitis Delta [Poster WED-395]. Paper presented at: European Association for the Study of the Liver (EASL); June 05-08, 2024; Milan, Italy.
5. Wedemeyer H, Aleman S, Blank A, et al. Final Results of MYR301: A Randomised Phase 3 Study Evaluating the Efficacy and Safety of BLV Monotherapy for Chronic Hepatitis Delta. [Presentation #LBO-004]. Paper presented at: European Association for the Study of the Liver; May 7–10, 2025; Amsterdam, the Netherlands.
6. Aleman S, Brunetto M, Blank A, et al. Predictors of undetectable hepatitis delta virus RNA at 48 weeks after end of treatment with bulevirtide monotherapy in the MYR 301 study. [Oral Presentation #OS-066]. Paper presented at: European Association for the Study of the Liver; May 7–10 2025; Amsterdam, the Netherlands.
7. Zoulim F, Asselah T, Aleman S, et al. Achieving Undetectable HDV RNA at End of Therapy With Bulevirtide With or Without PegIFN $\alpha$  is Strongly Associated With Posttreatment Virologic Response in CHD. [Presentation #OS-070]. Paper presented at: European Association for the Study of the Liver; May 7–10 2025; Amsterdam, the Netherlands.
8. Zoulim F, Asselah T, Aleman S, et al. Persistent Low Viremic Relapse vs High Viremic Relapse After the End of Treatment With Bulevirtide With or Without Pegylated Interferon in Patients With Chronic Hepatitis Delta Virus. [Poster #2245]. Paper presented at: The Liver Meeting, American Association for the Study of Liver Diseases; November 7–11, 2025; Washington, DC.
9. Wedemeyer H, Kahlhofer J, Degasperis E, et al. Controlled bulevirtide discontinuation in chronic hepatitis D: The D-SOLVE BUL-STOP Trial. Paper presented at: EASL Congress 2026; 27-30 May, 2026; Barcelona, Spain.
10. Fontaine H, Bourliere M, Subic M, et al. Is undetectability of HDV RNA for 96 weeks of Bulevirtide associated with a sustained virological response off-treatment in the real-life ? Results from the French ANRS/MIE HD EP 01 HEPDELTA Cohort [Oral Presentation]. Paper presented at: EASL Congress 2026; 27-30 May, 2026; Barcelona, Spain.
11. De Ledinghen V, Lacombe K, Pol S, et al. Sustained virological response after treatment with Bulevirtide in HDV patients. Data from the french multicenter real-life cohort [Poster WED-410]. Paper presented at: European Association for the Study of the Liver (EASL); June 05-08, 2024; Milan, Italy.
12. Asselah T, Chulanov V, Lampertico P, et al. Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D [Supplementary Appendix]. *N Engl J Med*. 2024;391(2):133-143.
13. Allweiss L, Volmari A, Manuilov D, et al. Bulevirtide in combination with pegylated interferon alfa-2a shows a sustained off-treatment response in the liver [Abstract]. Paper presented at: European Association for the Study of the Liver (EASL); June 05-08, 2024; Milan, Italy.

14. Wedemeyer H, Aleman S, Brunetto MR, et al. A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D. *N Engl J Med.* 2023;389(1):22-32.
- 

## Abbreviations

AE=adverse event  
BLV=bulevirtide-gmod  
CPT=Child-Pugh-Turcotte  
EOT=end of treatment  
FU=follow-up  
GGT= $\gamma$ -glutamyltransferase  
GT=genotype  
HBsAg=hepatitis B surface antigen

HDAG=hepatitis D antigen  
IFN=interferon  
LLOD=lower limit of detection  
LLOQ=lower limit of quantification  
LSM=liver stiffness measurement  
NUC=nucleos(t)ide analog  
OR=odds ratio

PEG-IFN $\alpha$ =pegylated interferon alpha  
Q=quartile  
SAE=serious adverse event  
SVR=sustained virologic response  
ULN=upper limit of normal

---

## Product Label

For the full indication, important safety information, and boxed warning(s), please refer to the Hepcludex US Prescribing Information available at:

[www.gilead.com/-/media/files/pdfs/medicines/hdv/hepcludex/hepcludex\\_pi](http://www.gilead.com/-/media/files/pdfs/medicines/hdv/hepcludex/hepcludex_pi).

## Follow-Up

For any additional questions, please contact Gilead Medical Information at:

☎ 1-866-MEDI-GSI (1-866-633-4474) or 🌐 [www.askgileadmedical.com](http://www.askgileadmedical.com)

## Adverse Event Reporting

Please report all adverse events to:

Gilead Global Patient Safety ☎ 1-800-445-3235, option 3 or

🌐 [www.gilead.com/utility/contact/report-an-adverse-event](http://www.gilead.com/utility/contact/report-an-adverse-event)

FDA MedWatch Program by ☎ 1-800-FDA-1088 or ✉ MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or 🌐 [www.accessdata.fda.gov/scripts/medwatch](http://www.accessdata.fda.gov/scripts/medwatch)

## Data Privacy

The Medical Information service at Gilead Sciences may collect, store, and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead's affiliates, business partners, service providers, and regulatory authorities located in countries besides your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement ([www.gilead.com/privacy-statements](http://www.gilead.com/privacy-statements)) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact [gilead.privacy@gilead.com](mailto:gilead.privacy@gilead.com).

HEPCLUDEX, GILEAD, and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or its related companies.

© 2026 Gilead Sciences, Inc